Xanodyne Announces New Executive Team Members

NEWPORT, Ky., July 13 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc., an
integrated specialty pharmaceutical company with both development and
commercial capabilities focused on women's healthcare and pain management,
today announced the appointment of three new members to its executive
management team. Joining the company are Natasha Giordano, Chief Commercial
Officer; Rita O'Connor, Chief Financial & Information Officer; and Peter
Wentworth, Senior Vice President, Human Resources.

Commenting on these appointments, CEO Michael J. Valentino said, "I am excited
to welcome Natasha, Rita, and Peter to the Xanodyne management team. Each of
them brings a diverse and proven track record of building and leading high
growth organizations within the pharmaceutical industry. Their collective
experience should contribute significantly to the anticipated rapid growth and
commercial success of our company."

Ms. Giordano has more than 25 years of experience in the healthcare and
pharmaceutical industry and most recently served as President Americas at
Cegedim Dendrite, a global sales and marketing solutions and information
company specializing in the pharmaceutical industry. Her depth of experience
includes senior leadership positions in general management, marketing,
compliance, and sales at major pharmaceutical companies including Pfizer and
Parke-Davis.

Ms. O'Connor joins Xanodyne from NPS Pharmaceuticals where she served as Vice
President, Finance. Previously, she was Chief Financial Officer and Treasurer
at Adams Respiratory Therapeutics. With nearly 20 years of finance and
accounting experience in the pharmaceutical industry, O'Connor is a certified
public accountant and has held leadership positions at Schering-Plough and
Deloitte & Touche. She also serves on the Board of Directors at the Essential
Group Inc.

Mr. Wentworth has extensive experience within the field of human resources,
including more than 25 years working in global healthcare and consumer
products industries. Most recently he was Executive Vice President, Human
Resources at Adams Respiratory Therapeutics. Wentworth is a seasoned business
leader, who has held a broad range of positions at major global companies such
as Pfizer, Warner-Lambert, and PepsiCo.

About Xanodyne

Xanodyne Pharmaceuticals, Inc., which commenced operations in 2001, is an
integrated specialty pharmaceutical company with both development and
commercial capabilities focused on women's healthcare and pain management.
Xanodyne markets a portfolio of products consisting of FDA approved
pharmaceuticals and a line of prenatal vitamins. Additionally, Xanodyne is
advancing a late stage pipeline of product candidates targeted at significant
potential markets in Xanodyne's focus areas.

SOURCE Xanodyne Pharmaceuticals, Inc.

Tom Jennings of Xanodyne Pharmaceuticals, Inc., +1-859-371-6383